Table 3.
Data on drug provocation testing (DPT) with biologics from the large cohort of patients of the RCUH (Ramon y Cajal University Hospital), Madrid, Spain
| Alvarez-Cuesta E, et al. Allergy. 2015 | Madrigal-Burgaleta R, et al. JACI: In Practice. 2019 | ||
|---|---|---|---|
| Results from all patients referred over three years after a DHR to biologics (n = 30) | Results from all referred patients over seven years after a DHR to biologics (n = 95) | ||
| DPT Result |
Biologics n = 30 |
DPT Result |
Biologics n = 95 |
| Negative DPT | 9/30 (30%) | Negative DPT | 47/95 (49%) |
| Positive DPT | 4/30 (13%) | Positive DPT | 13/95 (14%) |
| DPT not undergone |
17/30 (57%) |
DPT not undergone |
35/95 (37%) |
|
Results only from the patients who underwent DPT with biologics (n = 13) |
Results only from the patients undergoing DPT with biologics (n = 60) |
||
|
DPT Results |
Biologics n = 13 |
DPT Result |
Biologics n = 60 |
| Negative DPT | 9/13 (69%) | Negative DPT | 47/60 (78%) |
| Positive DPT |
4/13 (31%) |
Positive DPT |
13/60 (22%) |
|
Safety results from the patients with a positive DPT to biologics (n = 4) |
Safety results from the patients with a positive DPT to biologics (n = 13) |
||
|
Severity Brown classification |
Positive DPTs to biologics n = 4 |
Severity Brown classification |
Positive DPTs to biologics n = 13 |
| Grade 1 | 3/4 | Grade 1 | 5/13 (38%) |
| Grade 2 | 2/4 | Grade 2 | 7/13 (54%) |
| Grade 3 |
0/4 |
Grade 3 |
1/13 (8%) |
|
Alvarez-Cuesta E, et al. Allergy. 2015 |
Madrigal-Burgaleta R, et al. JACI: In Practice. 2019 |
||
n, number of patients; DPT, drug provocation test; DHR, drug hypersensitivity reaction.
This table has been modified from the data in the studies by Alvarez-Cuesta et al. and Madrigal-Burgaleta et al. to show only drug provocation test results from patients reacting to biologics.